Breaking Down Neurotrophic Keratitis: A Review and Discussion on the Latest Strategies to Diagnose and Treat (Archived CME Webcast)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Neurotrophic keratitis (NK) is characterized by disrupted tearing and progressive corneal damage that does not readily heal. Until very recently, a lack of effective treatment to reinnervate and heal eyes affected by NK served to further hamper efforts toward timely diagnosis. Now that an effective treatment is available, ophthalmologists need to identify patients who might benefit from treatment before the disease progresses to the point of corneal perforation and subsequent loss of visual acuity. The desired results of this educational activity are for ophthalmologists to have a better understanding of the pathophysiology of NK as well as current best practices for screening, diagnosis, and treatment.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Describe the pathophysiology of neurotrophic keratitis
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
- Review evidence of corneal healing and reinnervation in patients treated with recombinant human nerve growth factor
- Identify treatment strategies for patients diagnosed with any stage of neurotrophic keratitis
|Francis S. Mah, MD (Chair) |
Director, Cornea and External Diseases
Co-Director, Refractive Surgery
Scripps Clinic Torrey Pines
La Jolla, California
|Marjan Farid, MD|
Professor of Ophthalmology
Director of Cornea, Cataract, and Refractive Surgery
Vice Chair of Ophthalmic Faculty
Gavin Herbert Eye Institute
University of California, Irvine
|Stephen C. Pflugfelder, MD|
Professor of Ophthalmology
James and Margaret Elkins Chair
Baylor College of Medicine
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Marjan Farid, MD, is a consultant for Allergan; Bausch & Lomb Incorporated; Bio-Tissue; CorneaGen; Dompé US, Inc; Eyevance; Johnson & Johnson Vision Care, Inc; Kala Pharmaceuticals; and Novartis Pharmaceuticals Corporation.
Francis S. Mah, MD, is a consultant for Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Eyenovia, Inc, EyePoint Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, and Polyactiva Pty Ltd; is on the speakers bureau for Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Sun Pharmaceutical Industries, Inc; and has ownership interest in Avellino Labs, iVIEW Therapeutics, Inc, Ocular Science, Okogen, and Sydnexis.
Stephen C. Pflugfelder, MD, is a consultant for Dompé US, Inc, Kala Pharmaceuticals, and Kowa Pharmaceuticals America, Inc; and is a contracted researcher for Allergan and Dompé US, Inc.
Angie E. Wen, MD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dompé US, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.
This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 235